Top Markets
#1 PulseChain PulseChain +43.68%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.62%
#3 Meteora Meteora +7.65%
#4 Rocket Pool Rocket Pool +5.96%
#5 eCash eCash +5.95%
#6 Bitway Bitway +5.95%
#7 Bitcoin SV Bitcoin SV +5.63%
#8 Creditcoin Creditcoin +5.39%
#9 Fake World Assets Fake World Assets +5.22%
#10 EthereumPoW EthereumPoW +4.95%
Coin of the day
PulseChain PulseChain
Innstillinger
Språk
NORSK
Valuta
USD
Tema
IntelGenx Technologies Corp. IntelGenx Technologies Corp.

IntelGenx Technologies Corp.

IGX
Rangering i aksjer #28345
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Aksjekurs
$0.17446996
Sist synkronisert: 2024-06-11
Markedsverdi
$26.97M
Endring (1 dag)
-0.57%
Endring (1 år)
0.00%
Land
CA
Handel IntelGenx Technologies Corp. (IGX)

Kategori

Healthcare
P/E-forhold for IntelGenx Technologies Corp. (IGX)
P/E-forhold per 2026 TTM: 0
Ifølge IntelGenx Technologies Corp. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for IntelGenx Technologies Corp. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.